Quarterly Sales (Approved)
February 12, 2021 (Est)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: THIOLA® EC (tiopronin) for Cystinuria
WHAT IS THE CATALYST EVENT?
Report out on post-CRL FDA meeting
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Quarter's sales: $15M Q3/2020
2020 Revenue guidance: For the full year 2020, the Company anticipates net product sales will exceed the previous guidance of mid-single-digit percentage growth compared to 2019.
11-05-2020 Third Quarter 2020 Financial Results
MECHANISM OF ACTION
The goal of therapy is to reduce urinary cystine concentration below its solubility limit. Tiopronin is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of tiopronin-cysteine. From this reaction, a water-soluble mixed disulfide is formed and the amount of sparingly soluble cystine is reduced.
Updated by HC
TVTX, Cystinuria, persistent kidney stones, defective transepithelial transport of cystine and dibasic amino acids in the kidney and intestine, THIOLA® EC (tiopronin)
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post